Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone cream can be used on the scalp, but it may not be effective due to its dosage. AR antagonists like clascoterone are generally less effective than 5AR inhibitors for hair loss.

User has been shedding hair despite using finasteride for a year, increasing the dose recently, and experiencing thin, short hairs. Other users suggest continuing treatment, seeing a dermatologist, and note that some hair loss is normal.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Methylsulfonylmethane (MSM) is not a treatment for male pattern baldness but can accelerate hair growth and thicken miniaturized hairs, with the side effect of increased hair growth all over the body. The user asks others to share their experiences with MSM.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

A 23-year-old male experienced initial success with finasteride, topical minoxidil, and ketoconazole for hair loss, but persistent shedding and scalp issues led him to switch to dutasteride without improvement. Users suggest stress management, addressing potential seborrheic dermatitis, and patience with the treatment process.

The conversation discusses concerns about getting a buzz cut years after a FUE hair transplant due to an unnatural look and thinning hair. Suggestions include trying a buzz cut and considering scalp micropigmentation (SMP) as an option.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

Shampoos are unlikely to cause permanent hair loss; hair loss is more likely due to male pattern baldness (MPB). The user is advised that losing hair in the shower is normal, and to avoid shampoos with sodium sulfate.